Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)

Gepotidacin, a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development for treatment of uncomplicated urinary tract infection (uUTI). This phase 2a study in female participants with uUTI evaluated the pharmacokinetics (primary objective), safety, and exploratory efficacy of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Overcash, J. Scott, Tiffany, Courtney A., Scangarella-Oman, Nicole E., Perry, Caroline R., Tao, Yu, Hossain, Mohammad, Barth, Aline, Dumont, Etienne F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2020
Konular:
Clinical Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318048/
https://ncbi.nlm.nih.gov/pubmed/32284384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00199-20
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller